Skip to main content
Larimar Therapeutics, Inc. logo

Larimar Therapeutics, Inc. — Investor Relations & Filings

Ticker · LRMR ISIN · US98885E1038 LEI · 529900NCBZHTTJV6HX73 US Professional, scientific and technical activities
Open in API
Filings indexed 666 across all filing types
Latest filing 2016-04-04 Director's Dealing
Country US United States of America
Listing US LRMR

About Larimar Therapeutics, Inc.

https://larimartx.com/

Larimar Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. The company utilizes a proprietary intracellular delivery platform to design fusion proteins that deliver therapeutic molecules to targets within cells. Its lead product candidate, nomlabofusp (formerly CTI-1601), is a recombinant fusion protein being evaluated in a Phase 2 clinical program for the treatment of Friedreich's ataxia, a rare and progressive genetic disease. Larimar Therapeutics plans to leverage its platform to develop additional therapies for other rare diseases characterized by deficiencies in intracellular proteins.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2016-04-04 English
FORM 4 SUBMISSION
Director's Dealing
2016-04-04 English
FORM S-8
Regulatory Filings Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC, which is used to register securities to be offered under employee benefit plans such as stock option plans. It includes details about the stock option plan, the number of shares registered, and signatures of company officers. It is not a financial report, earnings release, or management discussion, but a regulatory filing related to securities registration. Therefore, it fits best under Regulatory Filings (RNS). The document length and content confirm it is a full registration statement, not just an announcement.
2016-03-15 English
10-K
Annual Report FY 2015
2016-03-15 English
FORM 3 SUBMISSION
Director's Dealing
2016-03-10 English
FORM 8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated March 9, 2016, by Zafgen, Inc. It announces the company's financial results for the fourth quarter of 2015 and the fiscal year ended December 31, 2015. The text states that a press release is furnished as Exhibit 99.1 and incorporated by reference. The document itself is short (2918 characters) and primarily serves to announce the earnings results via a press release rather than containing detailed financial statements or analysis. According to the classification rules, initial announcements of quarterly or annual financial results in the form of press releases or brief disclosures are classified as Earnings Release (ER). This is not a full annual report (10-K) or interim report (IR), nor is it a regulatory filing or report publication announcement. Therefore, the appropriate classification is Earnings Release (ER).
2016-03-09 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.